ACOUS085 Phase 2 Study to be Presented at Industry-Leading Conferences
Tübingen, Germany, August 12, 2024 – Acousia Therapeutics GmbH, a clinical stage biotech company focused on enhancing and preserving natural hearing, announced today that they will be presenting the ACOU085 Phase 2 PROHEAR clinical study at two prestigious conferences in the coming months.
The first presentation will take place at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston, Massachusetts from August 20-22, 2024. This will be followed by a presentation at the 36th World Congress of Audiology in Paris, France from September 19-22, 2024.
The PROHEAR study is a placebo-controlled Phase 2a study with a split-body design, investigating the effectiveness of ACOU085 in protecting patients with testicular cancer from hearing loss caused by high-dose, cisplatin-based chemotherapy regimens. This study has been endorsed by the Study Group of the German Society of Otorhinolaryngology and is being conducted across major university clinics in Germany under the supervision of the German Federal Institute for Drugs and Medical Devices and the European Medicines Agency.
Dr. Jonas Dyhrfjeld-Johnsen, CDO and Managing Director of Acousia Therapeutics, will be presenting the results of the PROHEAR study at both conferences. He will also be participating in roundtable and panel discussions at the HansonWade Summit and will be chairing the event.
“We are honored to have been invited to present our ongoing PROHEAR study to the international clinical community and our industry peers. This is a testament to the significant unmet medical need and long-lasting health consequences facing patients with acute forms of hearing loss, such as those caused by chemotherapy,” said Dr. Dyhrfjeld-Johnsen.
ACOU085, also known as Bimokalner, is a first-in-class, small-molecule drug candidate that is delivered using standard transtympanic administration in a proprietary, slow-release gel formulation. It targets the KCNQ4-encoded Kv7.4 potassium channel in the outer hair cells of the inner ear, which are responsible for hearing. In preclinical studies, ACOU085 has shown promising results in reducing cisplatin-induced hearing loss and preserving outer hair cells from ototoxicity.
For more information about the ACOU085 Phase 2 study or Acousia Therapeutics, please contact Tim Boelke, M.D. at boelke@acousia.com or visit www.acousia.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.